Divalproex Sodium
Product Images NDC 43353-547

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 43353-547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 500mg (43353 547)

Label for Divalproex Sodium extended-release tablets, 500 mg strength, containing 60 tablets. The label indicates storage instructions between 20-25 degrees Celsius, dispensation in a light-resistant container, and child safety warnings. Manufactured by Mylan Pharmaceuticals Inc., Morgantown, WV, and repackaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The product is prescription only (Rx).*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Divalproex Structural Formula (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 01)

Chemical structure diagram of Divalproex Sodium showing the arrangement of atoms and bonds within the molecule, including sodium ions and organic groups.*

FDA Label Image

Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 02)

A cumulative distribution plot graph showing the percentage reduction in CPS rate for patients treated with Divalproex Sodium Delayed-Release compared to placebo. The x-axis represents the percentage of patients, and the y-axis shows the percentage reduction in CPS rate, indicating patient improvement or worsening.*

FDA Label Image

Proportion Of Patients Achieving Any Particular Level Of Reduction Was Consistently Higher For High Dose Valproate Than For Low Dose Valproate (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 03)

A clinical efficacy chart depicting % reduction in CPS (Complex Partial Seizure) rate on the vertical axis against percentage of patients on the horizontal axis. It compares the effects of high dose versus low dose Divalproex Sodium delayed release, showing improvement and worsening trends in patients.*

FDA Label Image

Figure 3 Mean Reduction In 4-week Migraine Headache Rates (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 04)

A bar graph comparing two groups: placebo and Divalproex Sodium Extended-Release Tablets. The vertical y-axis ranges from 0 to 1.2, with the placebo bar showing a value of 0.6 and the Divalproex Sodium bar showing a value of 1.2, marked with an asterisk indicating statistical significance (p=0.006).*

FDA Label Image

Mylan Logo (B1b571ea 8447 4fc1 8dd1 16ae8211dbe1 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.